The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2022 | Microenvironmental stimuli in CLL and Richter’s syndrome: session highlights
In this video, Elisa ten Hacken, PhD, Dana Farber Cancer Institute, Boston, MA, shares some highlights from a session at ESH CLL 2022, which focused on the role of microenvironmental stimuli in chronic lymphocytic leukemia (CLL). Dr ten Hacken gives an overview of the topics that were covered in this session, including the role of toll-like receptor (TLR) signaling, tumor-associated macrophages, and T-cell dysfunction in CLL development and progression. Dr ten Hacken concludes by emphasizing the importance of this session and that further research is needed to better understand how microenvironmental stimuli influence the development of CLL and Richter’s syndrome. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
